Hillstream BioPharma, Inc.
HILS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $278 | $546 | $594 | $3,825 |
| G&A Expenses | $1,816 | $1,305 | $1,953 | $1,685 |
| SG&A Expenses | $1,816 | $1,305 | $1,953 | $1,685 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,094 | $1,851 | $2,547 | $5,510 |
| Operating Income | -$2,094 | -$1,851 | -$2,547 | -$5,510 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$8 | -$4 | $5 | $157 |
| Pre-Tax Income | -$2,102 | -$1,855 | -$2,542 | -$5,352 |
| Tax Expense | $0 | $0 | $0 | $20 |
| Net Income | -$2,102 | -$1,855 | -$2,542 | -$5,352 |
| % Margin | – | – | – | – |
| EPS | -0.34 | -0.64 | -1.96 | -4.14 |
| % Growth | 46.9% | 67.3% | 52.7% | – |
| EPS Diluted | -0.34 | -0.64 | -1.96 | -4.14 |
| Weighted Avg Shares Out | 6,242 | 2,877 | 1,296 | 1,296 |
| Weighted Avg Shares Out Dil | 6,242 | 2,877 | 1,296 | 1,296 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $13 | $155 |
| Interest Expense | $10 | $6 | $8 | -$30 |
| Depreciation & Amortization | $25 | $0 | $0 | -$95 |
| EBITDA | -$2,067 | -$1,851 | -$2,547 | -$5,477 |
| % Margin | – | – | – | – |